Drug facts
MoleculeWarfarin
Generics already compete: 6 makers on the market. 54 A-rated products from 6 makers substitute at the counter.
Coumadin was first approved by the FDA before 1982 under NDA 009218; the application holder is Bristol Myers Squibb Pharma Co. The Orange Book lists NDA 009218 as discontinued.
The latest NADAC for WARFARIN SODIUM 2.5 MG TABLET is $0.10 per unit (as of 10/28/2026).
Holder Bristol Myers Squibb Pharma CoApplication NDA 009218Approved before 1982
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Coumadin patent listed in the Orange Book Orange Book
02Competition
- Generics
- 6 generic makers Orange Book
- First generic approved
- 08/17/1982 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Warfarin profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.10 per unitWARFARIN SODIUM 2.5 MG TABLET, mid-priced of 9 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 02/15/2023Class II, Warfarin Sodium Tablets, Rising Pharmaceuticals FDA enforcement
04Product
- Application holder
- Bristol Myers Squibb Pharma Co Orange Book
- Application
- NDA 009218 Orange Book
- First approved
- before 1982 Orange Book
- Dosage forms
- tablet
- Routes
- oral
- Other brand names
- Jantoven
- Status
- NDA 009218 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.